PFE | Weekly | Haru Insights

Pfizer received EMA validation of its MAA for PF-07307405, its Lyme disease vaccine candidate, following strong Phase 3 VALOR trial results showing over 70% efficacy and an excellent safety profile—marking a pivotal regulatory milestone with potential to unlock a new, recurring revenue stream in a high-growth therapeutic area.
CEO Albert Bourla made a $1.00 million insider purchase of 38,000 shares at $26.34, signaling deep personal conviction in Pfizer’s long-term turnaround, innovation pipeline, and strategic positioning—especially in oncology and vaccine development—amplifying market confidence during a period of sector-wide skepticism.

Pfizer’s Lyme disease vaccine could become a first-in-class, high-margin, recurring revenue engine, with strong Phase 3 data and EMA validation putting it on a clear path to commercialization in a disease space with rising incidence and no current treatment.
The company’s deepening foothold in immuno-oncology and rare diseases through Seagen, Metsera, and partnerships suggests a credible, diversified growth engine beyond legacy products, with late-stage assets poised to redefine its future.
Bourla’s $1M insider buy is a powerful signal of confidence, reinforcing investor trust in PFE’s strategic pivot and innovation agenda at a time when market skepticism looms over pharma’s long-term viability.
Non-COVID product sales are surging, with Eliquis, Padcev, and Lorbrena all posting double-digit growth—evidence of a successful post-pandemic commercial reset and sustainable revenue resilience.
Regulatory momentum is building, with EMA validation of PF-07307405 underscoring Pfizer’s ability to deliver on critical late-stage development, validating its R&D infrastructure and clinical execution.

Pfizer Inc. (PFE)[Tv]